Sychedelic, a neurotechnology startup developing closed-loop wearable neuromodulation systems designed to help individuals relax, sleep, and focus better, raised $3.5 million in seed funding to launch its wearable neuromodulation headphones.
The investment round was co-led by Cultadvisors LLP, TurboStart, and IdeaBaaz (Kuberan Ventures).
According to the Global Wellness Institute, adaptive wellness technologies are becoming one of the fastest-growing sectors within consumer health innovation.
Sychedelic said the funding raised will support continued product development, manufacturing scale-up, global expansion, and additional investment into AI-enabled adaptive wellness systems and personalized cognitive experiences.
Unlike traditional brain wearables that often resemble medical devices or laboratory equipment, Sychedelic was intentionally designed as a lifestyle product that users can comfortably wear anywhere they already use headphones. The startup describes the product as a “3-in-1 cognitive wearable,” combining the functionality of music headphones, a smart wellness tracker, and neurostimulation in a single device.
According to Sychedelic, its headphones combine tDCS neurostimulation, binaural audio technology, and live HRV biofeedback to help users regulate cognitive and emotional states in real time. Rather than relying on stimulants like caffeine for focus or medication for sleep support, Sychedelic uses adaptive neurotechnology designed to help users naturally shift how they feel based on the moment — whether that means becoming calmer, more energized, mentally clear, or ready for sleep.
“The future of neurotech is the integration into daily wearables that aren’t only used for 20 minutes, but utilized throughout the day,” states Ria Rustagi, co-founder and CEO of Sychedelic.
“We wanted to create something people genuinely want to wear every day — headphones that look beautiful, feel natural, play music, and can also help you relax, focus, or fall asleep without depending on caffeine, supplements, or sleep medication.
Digital health companies, including neurotechnology startups, have secured more than $180 billion in funding to date, according to our recent Funding Database.
More recently, Osteoboost Health, a developer of FDA-cleared wearable therapy for osteopenia—clinically proven to reduce bone loss in the spine, raised $8 million in a fresh financing round to scale manufacturing, expand clinical research, and broaden the commercial reach of its medical device for low bone density. In another deal, Proteins.1, a Finland-based deep-tech diagnostics startup, raised $4.7 million in Pre-Seed funding.